0N4A.L - Vivesto AB
Vivesto AB
Gustav III:s Boulevard 46
5th floor
Solna 169 73
Sweden
46 18 50 54 40
https://www.vivesto.com
Sector(s):
Industry:
Full Time Employees: 18
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Erik Kinnmann Assoc. Prof., M.B.A., M.D., Ph.D. | Chief Exec. Officer | N/A | N/A | 1958 |
| Mr. Robert Maiorana | Head of Accounting & Acting CFO | N/A | N/A | 1960 |
| Mr. Kai Wilkinson | Chief Technical Officer | N/A | N/A | 1981 |
| Mr. Urban Ekelund | IR Mang. | N/A | N/A | N/A |
| Mr. John T. Cosby | Head of Regulatory Affairs | N/A | N/A | 1962 |
| Mr. Dzianis Babrou | Head of Product Devel. | N/A | N/A | N/A |
| Mr. Henrik Rönnberg | Chief Medical Officer of Animal Health | N/A | N/A | N/A |
| Maria Nilsson Hagberg | Head of Regulatory Affairs | N/A | N/A | N/A |
| Ms. Johanna Rostin | Chief Regulatory Officer | N/A | N/A | 1967 |
| Ms. Kia Bengtsson | Head of Clinical Devel. | N/A | N/A | 1969 |
Description
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Corporate Governance
Vivesto AB’s ISS Governance QualityScore as of June 1, 2023 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 1; Compensation: 10.
